Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Share-based Compensation (2024 - 2025)

Silence Therapeutics' Share-based Compensation history spans 2 years, with the latest figure at -$86000.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 102.16% year-over-year to -$86000.0; the TTM value through Dec 2025 reached $8.1 million, down 50.49%, while the annual FY2025 figure was $8.1 million, 50.49% down from the prior year.
  • Share-based Compensation for Q4 2025 was -$86000.0 at Silence Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.1 million in Q2 2024 and bottomed at -$86000.0 in Q4 2025.